1367.1

An open label, Phase Ia/Ib dose finding study with BI 894999 orally administered once a day in patients with advanced malignancies with repeated administration in patients with clinical benefit
Site Status
Queensland Children's Hospital (QLD)
John Hunter Children's Hospital (NSW)
Sydney Children's Hospital (NSW)
Monash Children's Hospital (VIC)
Royal Children's Hospital (VIC)
Women's and Children's Hospital (SA)
Perth Children's Hospital (WA)
Royal Hobart Hospital (TAS)
Children's Hospital at Westmead (NSW)
Starship Children's Hospital (NZ)
Christchurch Hospital (NZ)
Chris O'Brien Lifehouse
Peter MacCallum Cancer Centre
Prince of Wales Hospital
Princess Alexandra Hospital
Royal Adelaide Hospital
Sir Charles Gardiner Hospital
Westmead Adult Hospital
Calvary Mater Newcastle
Preparing to open
Open
Closed
Complete
Adult Sites These sites are not monitored. Status may vary.
Diagnosis Stage Newly Diagnosed, Relapsed/Refractory
National Sponsor Boehringer Ingelheim
Open Date 09/12/2020
Conditions Neoplasms <br>NUT Carcinoma
Patient Range >18 years
Disease Type Brain and Spinal (Central Nervous System) Tumours, Chest and Lung (Thoracic) Tumours, Digestive System Tumours, Disease Type, Endocrine Tumours, Eye Tumours, Genetic Tumour Syndromes, Head and Neck Tumours, Kidney (Renal) Tumours, Leukaemia / Lymphoma / Blood Disorders, Neuroblastoma and Ganglioneuroblastoma, Skin Tumours, Soft Tissue and Bone Tumours (Sarcoma)
Study Type Interventional
International Sponsor